News Image

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Provided By GlobeNewswire

Last update: May 12, 2025

Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling

First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026

Read more at globenewswire.com

APOGEE THERAPEUTICS INC

NASDAQ:APGE (6/13/2025, 8:00:01 PM)

After market: 44 -0.48 (-1.08%)

44.48

+2.62 (+6.26%)



Find more stocks in the Stock Screener

Follow ChartMill for more